ARDELYX, INC. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Ardelyx reported Q3 2026 total product revenue of $125.5M (+19% YoY), driven by IBSRELA revenue of $96.3M (+23% YoY) and XPHOZAH revenue of $29.2M (+7% YoY). The company maintains $285.3M in cash and investments (vs. $264.7M at Dec 31, 2025), reiterates FY2026 guidance (IBSRELA $350–$370M; XPHOZAH $110–$120M; operating expenses below $500M), and announced completion of Phase 3 ACCEL enrollment (CIC trial) ahead of schedule with topline data expected H2 2027. U.S. Patent No. 12,788,750 covering commercial formulations of both products issued November 10, 2026, expiring December 6, 2041.
Why this rating
Strong revenue growth (+19–23% YoY) and cash accumulation ($20.6M increase) are meaningful for a $924M company. Phase 3 enrollment completion and patent issuance are pipeline positives. However, net loss remains ($0.7M Q3; $55M YTD), gross margin is high (95%) but OpEx is rising; path to profitability unproven. Growth trajectory is solid but not yet transformational; scale remains modest relative to company valuation.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.